CINGAL Drug Insight

“CINGAL Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about CINGAL for chronic pain in the US market. A detailed picture of the CINGAL for chronic pain in the United States for the study period 2019 –2032 is provided in this report along with a detailed description of the CINGAL for chronic pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CINGAL market forecast analysis for chronic pain in the US, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic pain.

Drug Summary

CINGAL is an approved combination viscosupplement formulated to provide the benefit of a cross-linked hyaluronic acid (HA) and a fast-acting steroid to effectively treat the symptoms associated with osteoarthritis (OA). It is a powerful, first-in-class treatment that combines the benefits of Anika’s proprietary HA formulation of MONOVISC, proven to deliver up to 6 months of relief of the symptoms of OA, with a well-established FDA-approved steroid, triamcinolone hexacetonide (TH), to treat inflammation and provide additional short-term pain relief. Cingal extends the benefits of Anika’s proprietary HA formulation to a broader range of patients across the spectrum of osteoarthritis pain.

CINGAL is uniquely formulated as a hyaluronic acid (HA) viscosupplement plus corticosteroid combination injection. CINGAL supplements the reduced amount of natural hyaluronic acid found in the synovial fluid in osteoarthritic knee joints, while the steroid component treats inflammation and provides fast pain relief within days of injection. The high concentration and total dose of hyaluronic acid in CINGAL combined with a well-established corticosteroid create a fast-acting high viscosity solution that cushions normal physical activities like walking and biking. With one single injection, CINGAL lubricates, cushions, and protects the knee joint, allowing patients to quickly return to their active lifestyles with reduced pain.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the CINGAL description, mechanism of action, dosage and administration, research and development activities in chronic pain.
• Elaborated details on CINGAL regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CINGAL research and development activities in chronic pain across the United States.
• The report also covers the patents information with expiry timeline around CINGAL.
• The report contains forecasted sales of for chronic pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic pain.
• The report also features the SWOT analysis with analyst views for CINGAL in chronic pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CINGAL Analytical Perspective by DelveInsight

In-depth CINGAL Market Assessment

This report provides a detailed market assessment of CINGAL for chronic pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

CINGAL Clinical Assessment

The report provides the clinical trials information of CINGAL for chronic pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for chronic pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CINGAL dominance.
• Other emerging products for chronic pain are expected to give tough market competition to CINGAL and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CINGAL in chronic pain.
• Our in-depth analysis of the forecasted sales data of CINGAL from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CINGAL in chronic pain.

Key Questions

• What is the product type, route of administration and mechanism of action of CINGAL?
• What is the clinical trial status of the study related to CINGAL in chronic pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CINGAL development?
• What are the key designations that have been granted to CINGAL for chronic pain?
• What is the forecasted market scenario of CINGAL for chronic pain?
• What are the forecasted sales of CINGAL in the United States? 
• What are the other emerging products available and how are these giving competition to CINGAL for chronic pain?
• Which are the late-stage emerging therapies under development for the treatment of chronic pain?